Literature DB >> 33800494

Identification of Overexpressed Genes in Malignant Pleural Mesothelioma.

Federica Morani1, Luisa Bisceglia1, Giulia Rosini1, Luciano Mutti2, Ombretta Melaiu1,3, Stefano Landi1, Federica Gemignani1.   

Abstract

Malignant pleural mesothelioma (MPM) is a fatal tumor lacking effective therapies. The characterization of overexpressed genes could constitute a strategy for identifying drivers of tumor progression as targets for novel therapies. Thus, we performed an integrated gene-expression analysis on RNAseq data of 85 MPM patients from TCGA dataset and reference samples from the GEO. The gene list was further refined by using published studies, a functional enrichment analysis, and the correlation between expression and patients' overall survival. Three molecular signatures defined by 15 genes were detected. Seven genes were involved in cell adhesion and extracellular matrix organization, with the others in control of the mitotic cell division or apoptosis inhibition. Using Western blot analyses, we found that ADAMTS1, PODXL, CIT, KIF23, MAD2L1, TNNT1, and TRAF2 were overexpressed in a limited number of cell lines. On the other hand, interestingly, CTHRC1, E-selectin, SPARC, UHRF1, PRSS23, BAG2, and MDK were abundantly expressed in over 50% of the six MPM cell lines analyzed. Thus, these proteins are candidates as drivers for sustaining the tumorigenic process. More studies with small-molecule inhibitors or silencing RNAs are fully justified and need to be undertaken to better evaluate the cancer-driving role of the targets herewith identified.

Entities:  

Keywords:  MPM; RNAseq; gene signature; malignant pleural mesothelioma; overexpressed genes; therapeutic targets

Mesh:

Substances:

Year:  2021        PMID: 33800494      PMCID: PMC7962966          DOI: 10.3390/ijms22052738

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  63 in total

1.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

Review 2.  SPARC-p53: The double agents of cancer.

Authors:  Denise Camacho; Joana P Jesus; António M Palma; Sofia A Martins; Alexandre Afonso; Maria Leonor Peixoto; Christopher J Pelham; Eduardo Moreno; Rajan Gogna
Journal:  Adv Cancer Res       Date:  2020-07-21       Impact factor: 6.242

3.  Identification of a human mitotic checkpoint gene: hsMAD2.

Authors:  Y Li; R Benezra
Journal:  Science       Date:  1996-10-11       Impact factor: 47.728

4.  Tenascin-X is a novel diagnostic marker of malignant mesothelioma.

Authors:  Yuan Yuan; Dag André Nymoen; Helene Tuft Stavnes; Anne Katrine Rosnes; Ola Bjørang; Chuanyue Wu; Jahn M Nesland; Ben Davidson
Journal:  Am J Surg Pathol       Date:  2009-11       Impact factor: 6.394

5.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

6.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

7.  ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells.

Authors:  M Mousli; R Hopfner; A-Q Abbady; D Monté; M Jeanblanc; P Oudet; B Louis; C Bronner
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

8.  Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis.

Authors:  Zhanwei Wang; Dionyssios Katsaros; Yi Shen; Yuanyuan Fu; Emilie Marion Canuto; Chiara Benedetto; Lingeng Lu; Wen-Ming Chu; Harvey A Risch; Herbert Yu
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

9.  A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.

Authors:  Steven C Kao; Michaela B Kirschner; Wendy A Cooper; Thang Tran; Sjaak Burgers; Casey Wright; Tiny Korse; Daan van den Broek; James Edelman; Michael Vallely; Brian McCaughan; Nick Pavlakis; Stephen Clarke; Mark P Molloy; Nico van Zandwijk; Glen Reid
Journal:  Br J Cancer       Date:  2016-02-18       Impact factor: 7.640

View more
  4 in total

1.  Identification of Novel Diagnostic Markers for Malignant Pleural Mesothelioma Using a Reverse Translational Approach Based on a Rare Synchronous Tumor.

Authors:  Tomoaki Naka; Yutaka Hatanaka; Yukiko Tabata; Akira Takasawa; Hideo Akiyama; Yasuhiro Hida; Hiromi Okada; Kanako C Hatanaka; Tomoko Mitsuhashi; Kei Kushitani; Vishwa Jeet Amatya; Yukio Takeshima; Kouki Inai; Kichizo Kaga; Yoshihiro Matsuno
Journal:  Diagnostics (Basel)       Date:  2022-01-27

2.  Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health.

Authors:  Luigi Vimercati; Domenica Cavone; Francesco Fortarezza; Maria Celeste Delfino; Romina Ficarella; Angela Gentile; Angela De Palma; Giuseppe Marulli; Luigi De Maria; Concetta Caporusso; Andrea Marzullo; Antonio d'Amati; Daniele Egidio Romano; Antonio Caputi; Stefania Sponselli; Gabriella Serio; Federica Pezzuto
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

Review 3.  Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.

Authors:  Francesca Napoli; Angela Listì; Vanessa Zambelli; Gianluca Witel; Paolo Bironzo; Mauro Papotti; Marco Volante; Giorgio Scagliotti; Luisella Righi
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

4.  A panel of emerging EMT genes identified in malignant mesothelioma.

Authors:  Licun Wu; Shaheer Amjad; Hana Yun; Sendurai Mani; Marc de Perrot
Journal:  Sci Rep       Date:  2022-01-19       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.